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ABSTRACT:
Cardiovascular disease (1) is the leading cause of death in the world. In the
United States alone, the American Heart Association estimates the cost of treating CVD
in 2009 to be $475.3 billion(2). Suitable autologous blood vessels are often scarce,
especially for patients who require multiple procedures. There is a global demand for
improved, biocompatible vascular conduits to address these shortcomings. Biodegradable
tubular scaffolds are currently being evaluated as vascular grafts in the surgical treatment
of cardiovascular disease. Seeding scaffolds with bone marrow-derived mononuclear
cells (BMCs) prior to implantation has been shown to significantly improve outcomes.
However, the role these cells play is poorly understood.
Various inferior vena cava (IVC) interposition models in recipient mouse models
were used to evaluate the developmental remodeling process of engineered blood vessels.
Detailed analysis of vascular graft morphology and CT imaging provide standardization
of graft analysis for various TEVG models. Seeding scaffolds with BMCs significantly
improved patency rates and graft development. However, seeded BMCs did not directly
contribute to the cellularity of the developing vessel, and were not detectable by three
weeks. Rather, BMCs were found to produce significant amounts of various cytokines in
response to the scaffold biomaterials, resulting in early recruitment of recipient mouse
monocytes to the scaffold and subsequent improvement in vascular neotissue formation.
A series of cell-tracking experiments demonstrate vascular cell in-growth from adjacent
vascular tissue. These results indicate that engineered blood vessels mature through an
early cytokine induced inflammatory response that induces native tissue regeneration.
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PART	
  I.	
  Vascular	
  Tissue	
  Engineering	
  Overview	
  
Background:	
  	
  	
  
Cardiovascular disease (CVD) is the leading cause of death in the world.
Ischemic heart disease, cerebrovascular disease and peripheral vascular disease account
for 13 millions deaths annually(3). Additionally congenital heart disease, which
represents the most common birth defect affecting nearly 1% of all live births, remains a
leading cause of death in the newborn period. In the United States alone, the American
Heart Association estimates the cost of treating CVD in 2009 to be $475.3 billion(2).
For end-stage cardiovascular disease in adults, or in children with congenital
cardiovascular anomalies, surgical reconstruction remains the treatment of choice.
Unfortunately there is a relative paucity of autologous tissue available for reconstructive
surgeries, necessitating the use of synthetic materials.
Biomaterials available in the cardiovascular surgeon’s armamentarium include
autologous vessels and prosthetic materials. Autologous tissue is superior to prosthetic
materials such as Goretex®, as prosthetics are more prone to thrombosis, infectious
complications, neointimal hyperplasia, and accelerated atherosclerosis(4-7). In an adult
patient undergoing multiple cardiac or peripheral vascular procedures, however, suitable
autologous tissue may be scarce due to the diffuse nature of atherosclerosis. Additionally,
in children undergoing surgery for complex congenital heart defects, repairs may be
extra-anatomic and require more autologous tissue than is available. Clearly, there is
demand for improved, biocompatible vascular conduits in these populations.
The great promise and hope of vascular tissue engineering is the development of
biological substitutes that restore, maintain or improve tissue function. The origins of
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vascular tissue engineering can be traced back to Alexis Carrel who received the Nobel
Prize in medicine for his early work in vascular biology. This established the basic
principles that provided the foundation for vascular surgery. Later in his career while
working in collaboration with Charles Lindbergh at the Rockefeller Institute, some of the
early pioneering work in cell culture was performed. In their manuscript entitled “The
Culture of Whole Organs,” Carrel and Lindbergh postulated that cell culture would one
day be used to grow entire organs(8). However it was not until Weinberg and Bell’s
seminal paper in 1986 that Lindberg and Carrel’s prediction became a reality for vascular
tissue(9). This search led to many advances in our basic understanding of tissue
interactions, including the critical importance of cellular and matrix interactions, the
modulation of cellular recruitment, growth and differentiation, as well as a deeper
appreciation for the challenges that are faced in attempting to apply these discoveries
clinically. The purpose of this introduction is to guide the reader through the major
milestones of vascular tissue engineering while providing in detail rationale for the
importance of continued scientific investigations, including this current study, aimed at
reducing the tremendous burden of cardiovascular disease.
Historical	
  Overview	
  
The first report of the use of synthetic vascular grafts dates back to 1952 when
Voorhees et al.. used Vinyon N cloth tubes as arterial interpositions in dogs(10-13).
Prior to this report, scientists were focused on using native arteries as conduits(10, 13).
In the ensuing years, other synthetic materials aimed at passively transporting blood with
minimal reaction were developed, leading to the clinical success of polyethylene
terephthalate (Dacron) and expanded poly tetrafluoroethylene (ePTFE).
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Major achievements in creating an ideal conduit have driven the continued search
for the best strategy to create fully functioning blood vessel substitutes.

In 1986,

Weinberg and Bell’s landmark publication described the use of bovine cells with rat
collagen gel to create an artificial blood vessel model. In 1998, Shinoka et al., first
described the use of a biodegradable synthetic scaffold with ovine cells, demonstrating
long-term autologous implantation in a low pressure pulmonary artery system(14). Also
in 1998, L’Heureux et al., published their creation of an engineered graft that used human
cells and was tested as a short-term xenogeneic implant in a high pressure arterial bypass
model(15). In 1999, Nicklason et al. and Shum-Tim et al. described the creation of an
artery grown in-vitro using autologous porcine/ovine cells on a biodegradable
polymer(16, 17). In their studies, Niklason et al., used small diameter grafts, and studied
their vessels under arterial pressures in the short-term. Shum-Tim et al., developed large
diameter grafts, studied under lower pressures with long-term evaluation of function.
In 2001, Shin’oka et al., reported the first clinical use of a tissue-engineered
vascular construct. The vascular graft was implanted in a four-year old girl to reconstruct
an occluded pulmonary artery, after a previous Fontan procedure(18). In another major
milestone for vascular tissue engineering, in 2007 L’Heureux et al. used their sheet-based
tissue engineered blood vessel clinically as replacements for failing arteriovenous
shunts(19).

Despite these tremendous achievements, the field has yet to report the

clinical use of a tissue-engineered vascular construct as a fully arterial interposition in
humans.

Further, the mainstay therapy for vascular reconstruction continues to be

autologous arteries and veins. In the following pages we will detail these early successes,
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discuss the applications of vascular tissue engineering in clinical trials, and describe the
frontiers of our technology.

Critical	
  Elements	
  of	
  an	
  Artificial	
  Blood	
  Vessel	
  	
  	
  
Synthetic vascular grafts were developed for patients with insufficient autologous
tissue for bypass grafting. These grafts have reasonable safety profiles, satisfactory
surgical handling characteristics (i.e. suture retention), and are available “off-the-shelf”
for use as large caliber bypass grafts. Currently available synthetic vascular conduits,
however, have several significant limitations. These grafts have no growth potential, thus
many pediatric patients will “outgrow” the graft and require re-operation. Re-do
operations are associated with an increased risk of complications and death.
Bioprosthetic materials such as gluteraldehyde-fixed xeno- or allografts used for grafting
are prone to ectopic calcification, resulting in poor durability.

Both prosthetic and

bioprosthetic materials are prone to infection, putting the patient at risk for sepsis, graft
rupture, distal septic emboli, as well as re-operation for explantation of graft material.
Lastly, the use of synthetic grafts as small caliber bypass grafts is limited as they are
prone to thrombosis and neointimal hyperplasia, likely from a lack of biocompatibility
and an inability to repair and remodel.
Tissue-engineered vascular conduits address the shortcomings of currently
available vascular conduits.

The ideal tissue-engineered graft possesses excellent

surgical handling characteristics. An experienced surgeon must be able to handle the
graft, modify it as necessary for the patient’s anatomy, perform anatosmoses using
standard surgical technique and instrumentation, and obtain hemostasis immediately
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following implantation. Because of the morbidity and mortality associated with longer
operative and anesthetic time, the surgeon must perform these anastomoses in a timely
fashion. Optimally, tissue-engineered grafts would be available “off-the shelf” (similar to
prosthetic grafts), and require minimal manipulation other than seeding the cell on the
substrate the day of surgery.
In addition to satisfactory surgical handling techniques, the ideal tissueengineered vascular graft is biocompatible. The polymerized scaffold or decellularized
matrix should degrade over time, leaving intact vascular neotissue that provides the
structural integrity for the conduit. The degradation of scaffold materials results in a
completely biocompatible structure that is not prone to infection or ectopic calcification,
and does not require immunosuppression.

Finally, the ideal tissue-engineered graft

possesses the intrinsic ability to grow with the patient, obviating the need for reoperations in the pediatric population.
The most important characteristic of a tissue-engineered vascular graft is,
however, recapitulation of vessel form and function. Put simply, grafts implanted in the
arterial and venous circulation should mirror as closely as possible the native artery and
vein. The ideal arterial interposition graft possess a functional, confluent, nonthrombogenic endothelium and a thick smooth muscle laden tunica media that can
accommodate mean arterial pressure and constrict appropriately to ensure perfusion to
end-organs during low flow states. Thus, the intrinsic mechanical strength of the seeded
scaffold should be higher and the degradation time longer in arterial grafts than in venous
grafts where mechanical integrity is less critical but adequate compliance is necessary.
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Approaches	
  to	
  creating	
  TEBVs	
  
The	
  first	
  artificial	
  artery:	
  Weinberg	
  and	
  Bell	
  	
  	
  
The first reported successful construction of a tissue-engineered vascular graft
came from Weinberg and Bell in 1986. Prior work had established the use of synthetic
materials as vascular conduits, albeit not for small diameter vessels (<6mm diameter),
and autologous tissue had become the mainstay of vascular repair. Building on previous
reports of partial vascular constructs, including in vitro growth of endothelial cells and
models of the vascular wall in mock circulatory loops, this seminal paper reported
culturing bovine vascular cells to seed a collagen matrix in an tubular mold(9, 20).
Specifically, bovine smooth muscle cells were combined with collagen using a
casting culture medium to create a tubular lattice. After a week of culture, a synthetic
Dacron sleeve was placed on the outer surface of the construct, and seeded with
fibroblasts to create a neo-adventitia. After another two weeks, the grafts were seeded
with endothelial cells and left in a rotational culture (1rev/min) for one week. This
procedure provided a template for the creation of a tubular cellular structure that
demonstrated extracellular matrix deposition of collagen, alignment of smooth muscle
cells and a confluent endothelial cell layer, in a construct that had burst pressures of up to
323 mmHg when reinforced with added layers of Dacron. This led the authors to describe
the use of their graft as a model for the study of the biological properties of blood vessels,
rather than as a potentially clinically useful construct.

Despite these shortcomings,

Weinberg and Bell laid the foundation and provided a roadmap for scientists to develop
artificial blood vessels, as their publication marked the birth of vascular tissue
engineering.
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First	
  clinical	
  use	
  of	
  a	
  TEBV	
  	
  
Congenital cardiac anomalies, a diverse spectrum of defects, result in significant
perinatal morbidity and mortality. Untreated single ventricle anomalies are associated
with 70% mortality in the first year of life.

The therapy of choice is surgical

reconstruction. Without surgery, survival of this cohort into adulthood is rare. Initially
described in 1971, the Fontan operation separates pulmonic and systemic blood flow;
subsequently decreasing the incidence of chronic hypoxia and high output cardiac failure.
This suite of procedures requires a synthetic graft, commonly Polytetrafluoroethylene
(PTFE, or Gore-Tex®). As mentioned above, PTFE has several limitations, including
potential for infection, thrombosis, and ectopic calcification(21-23). Furthermore, PTFE
does not grow, resulting in patients “outgrowing“ the graft and requiring re-operation, or
suffering complications related to intentional graft over-sizing.
The fabrication and seeding of biodegradable polymer scaffolds for use in humans
was an outgrowth of work performed in large animal models. Precursors to the clinical
study included the creation of a tissue-engineered heart valve by Zund and others(24-27).
This valve construct consisted of biodegradable polyglycolic acid fibers serially seeded
with fibroblasts and endothelial cells. These tissue-engineered valvular constructs were
implanted in the pulmonary valve position in juvenile lambs. Functional performance of
the grafts was satisfactory on ultrasound, and histological analysis revealed appropriate
cellular architecture. These results were validated by a larger study with acellular valve
controls, in which the seeded scaffolds demonstrated superior functionality(28).
The natural extension of tissue-engineered heart valves was the creation of tissueengineered vascular conduits. These tubular constructs could be fabricated from the
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same scaffold materials and cellular elements, with the additional advantage of less
complex biomechanical constraints(17, 29, 30).
Although both tissue-engineered heart valves and blood vessels demonstrated
mechanical integrity and vascular neotissue formation in vivo, the original seeding
models relied on time-consuming expansion of endothelial cells and smooth muscle cells
in vitro. This made experiments time consuming and vulnerable to culture contamination,
in addition to limiting the practicality of human use, as each patient would require
multiple(31). Attention was turned to other sources of seeded cells, with a focus on cells
that could be procured on the day of surgical implantation of tissue-engineered grafts.
Seeking an abundant cell source that did not require ex vivo tissue culture expansion,
Matsumura and colleagues seeded polymer scaffolds with autologous bone marrow and
implanted these constructs into the inferior vena cava of dogs(32, 33). Not only did these
grafts remain patent, histological analysis revealed cell populations elaborating vascular
endothelial growth factor (VEGF) and expressing endothelial or smooth muscle cell
markers(32).
The first reported use of a tissue-engineered graft in humans occurred in 1999, in
a four-year-old girl with a single right ventricle and pulmonary atresia(18). At the age of
three she had undergone pulmonary artery angioplasty and the Fontan procedure.
Subsequent angiography revealed total occlusion of the right intermediate pulmonary
artery. A two-centimeter segment of peripheral vein was explanted and cells expanded ex
vivo. Cells were seeded onto a caprolactone–polylactic acid copolymer scaffold,
reinforced with woven polyglycolic acid.
successfully

reconstructed

with

the

The occluded pulmonary artery was

tissue-engineered graft.

No

postoperative
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complications were reported. On follow-up angiography, the transplanted vessel was
patent with no signs of aneurismal dilation.
Promising large animal study data and the first successful human application of a
tissue-engineered graft provided the impetus for a larger clinical study. From May 2000
to December 2004, 25 patients (mean age 5.5 years) with single ventricle physiology
were implanted with tissue-engineered grafts at Tokyo Women’s Medical University.
Extra cardiac total cavopulmonary connection (EC TCPC) conduits (a connection
between the vena cava and the pulmonary arteries) for surgical correction of single
ventricle physiology represented an ideal hemodynamic starting point for tissueengineered grafts in humans. In this system, high flow rates minimize thrombotic risks
while relatively low pressure minimizes wall tension on the conduit. This pilot study
evaluated two types of scaffolds, PCLA-PGA (n=11) and PCLA-PLA (n=14).
Autologous bone marrow (5 milliliters/kilogram body weight), aspirated from the
patient’s ilium under general anesthesia, was used to seed the polymer scaffold and the
construct was incubated for two hours in media prior to implantation. All 25 patients
survived to hospital discharge(34).

Duplex ultrasonography, computed tomography,

magnetic resonance angiography, and cineangiography were utilized for graft
surveillance. All grafts remained patent, and no aneurismal dilation was detected with
any imaging modality(35). Of note, six patients developed silent graft stenosis, and four
underwent successful balloon angioplasty. Four patients died during follow-up (mean
follow-up 5.8 years). The causes of death, however, were not related to tissue-engineered
graft dysfunction; all four patients had imaging demonstrating a widely patent graft prior
to death. Of the 21 surviving patients, 18 were classified as New York Heart Association
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(NYHA) Class I (no impairment of physical activity) and 3 were classified as NYHA
Class II (mild impairment of physical activity).
Although the Tokyo Women’s study remains a landmark in tissue engineering,
this data represents a single institutions experience and patients were not randomized.
Additionally, although autologous bone marrow cells remain an attractive cell source for
tissue-engineered graft seeding, no histological specimens exist from this clinical trial
(autopsies are not usually performed in Japan, and most patients are still alive). The fate
of seeded bone marrow, the optimal seeded cell number, and the role of post-operative
anticoagulation remains to be determined.

Sheet-based	
  tissue	
  engineering	
  	
  
In the continuing search for an ideal conduit to repair damaged human vessels,
L’Heureux et al. employed a new methodology to produce human vessels in vitro. Sheetbased tissue engineering (SBTE) employs confluent sheets of cells, and the abundant
ECM they synthesize, that are grown into tubular structures to create a vessel-like
structures. In developing SBTE, L’Heureux et al. sought to overcome the need to use
synthetic material for structural support of biological grafts as was the case for Weinberg
and Bell (9, 15, 36). In this approach only cellular components were employed in the
creation of their artificial blood vessel.
The first TEVG produced by SBTE contained only human skin fibroblasts cultured
from dermal specimens removed during reductive breast surgery; smooth muscle cells
and endothelial cells were isolated from newborn umbilical veins or adult saphaneous
veins. Nonetheless, it had a burst pressure of 2594 ±501 mmHg (15, 37). Cell sheets were
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produced in culture medium supplemented with 50 ug/ml of sodium ascorbate, peeled off
from culture flasks and tubularized around inert tubular support cylinders. After a
maturation period of at least 8 weeks, the sheets become cohesive tubes that can be
seeded with endothelial cells. The endothelial layer of the constructs expressed von
Willenbrand factor immunohistochemical staining and demonstrated ac-LDL uptake;
smooth muscle cells stained positively for alpha-smooth muscle actin and desmin.
Fibroblasts did not stain for smooth muscle cell markers, but expressed vimentin and
synthesized elastin, which organized in circular arrays. The ECM contained laminin,
fibronectin, chondroitin sulfates and various collagen subtypes. Further research
demonstrated that these artificial blood vessels retained concentration dependent
contractile properties, responsive to various vasoconstricting (histamine, bradykinin,
ATP) and vasodilating (sodium nitroprusside, SIN-1, forskolin) agents with and without
inhibitory agents(37).
In the following years, the model was simplified to exclude smooth muscle cells
and was shown to be feasible using skin fibroblasts and venous endothelium isolated
from elderly patients with cardiovascular disease.

Pre-clinical studies in

immunodeficient nude rats, evaluated for up to 225 days, demonstrated patency rates of
85% without aneurism as abdominal aorta interpositional grafts. To study the in vivo
development of these grafts in a more representative biomechanical environment, the
tissue-engineered blood vessels were implanted in immunosuppressed cynomolgus
primates. Explants at 6wks and 8wks demonstrated patent vessels with no signs of
luminal narrowing or aneurismal formation. Alpha-actin positive smooth muscle cells
and proteoglycan expression was also observed in both models(37, 38).
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In 2007, L’Heureux and McAllister reported the second clinical use of vascular
tissue-engineered constructs when they described the implantation of their tissueengineered vascular graft in 3 patients undergoing hemodialysis treatment(19). These
dialysis patients had a history of previously failed access grafts. After 24 patient-months
of follow up for this cohort, only one of the grafts used for dialysis access had a
thrombogenic failure, secondary to low postoperative flow rate and moderate dilatation of
the graft. McAllister et al. then expanded their cohort to 10 patients in total, drawing
from two centers, in Argentina and in Poland(39). Three out of the ten implanted grafts
failed within the safety phase of their study, and one patient required surgical reintervention to maintain patency at 11 months. These results are consistent with the
expected failure rates with native hemodialysis access grafts (fistula) in such high-risk
patient populations.

Overall, after six months, the artificial grafts implanted as

hemodialysis access grafts had a 60% primary patency rate which is superior to that of
the standard of care synthetic graft (ePTFE).

Stem	
  Cells	
  for	
  Vascular	
  Tissue	
  Engineering	
  	
  
During the past decade, significant attention has been turned to the use of stem
cells in tissue engineered vascular grafts. Stem cells and endothelial progenitor cells can
differentiate into vascular lineages and thus have the potential to repair vascular systems.
Despite their obvious potential in clinical practice, there still remain many controversies
regarding how EPCs actually enhance endothelial repair and neovascularization(40).
Additionally, because of the limited expansion ability of EPCs, expansion of sufficient
EPC populations for therapeutic angiogenesis remains a significant impediment for most
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investigators. On the other hand, embryonic stem cells have an extensive self-renewal
activity and can be expanded without limit, thus ES-cell-derived endothelial cells may be
feasible as a novel cell source for therapeutic angiogenesis(41, 42).
Nourse and colleagues used VEGF to induce differentiation of functional
endothelium from human embryonic stem cells(43). Continuous VEGF treatment of
embryonic stem cells resulted in a 4- to 5-fold enrichment of CD31(+) cells but did not
increase endothelial proliferation rates, suggesting a primary effect on differentiation.
CD31(+) cells purified from differentiating embyroid bodies up-regulated ICAM-1 and
VCAM-1 in response to TNF-α, confirming their ability to function as endothelial cells.
Collagen gel constructs containing the human embryonic stem cell derived endothelial
cells and implanted into infarcted nude rat hearts formed dense networks of patent vessels
filled with host blood cells. Thus Nourse et al. demonstrated the ability of human
embryonic stem cell derived endothelial cells to facilitate neovascularization of tissueengineered constructs.
In addition to driving ES cells into an endothelial lineage, investigators have
turned to embryonic stem cell derived smooth muscle cells as a potential cell source in
cardiovascular tissue engineering(44, 45). NADPH oxidase (Nox4) over-expression in
embryonic stem cell culture resulted in increased smooth muscle cell marker production,
whereas knockdown of Nox4 induced a decrease in production. Moreover, Nox4 was
demonstrated to drive smooth muscle differentiation through generation of H2O2(46).
Thus Nox4 expression maintains differentiation status and functional features of stem
cell-derived smooth muscle cells, highlighting its impact on vessel formation in vivo. It is
clear that embryonic stem cells and endothelial progenitor cells will be important in

19
vascular tissue engineering in the future, and endothelial cell and smooth muscle cells
derived from embryonic stem cell culture will require further characterization.
Autologous, readily available, bone marrow mononuclear cells (BMC) in both
human and animal models promote angiogenesis, early endothelialization, and contain
multi-potent cells that can also form part of the growing neovessel (47). In trying to
develop a TEVG, Matsumana et al, reported initial success with the use of harvested
vessel wall cells after isolation and culture. They found that this was a time consuming
process that required previous hospitalization for vessel harvesting and that in half of the
cases they were not able to obtain sufficient cells on the day of surgery. As a result, this
group turned to BMC as the cell source for their constructs, removing the impediments of
long-term cell culture and contamination, and more importantly, providing sufficient cells
for the seeding of biodegradable scaffolds (35, 48-50). In the first human clinical trial
with long term follow up (51), twenty-five TEVG were implanted using autologous BM
derived mononuclear cells with no evidence of aneurysm formation, graft rupture, graft
infection, or ectopic calcification; four patients had graft stenosis and underwent
successful percutaneous angioplasty. These initial findings demonstrated the feasibility
and safety of this technique and provided evidence for the use of BMC for the
construction of tissue engineered vascular graft. (Clinical studies described in detail in
section 3.2)

Summary	
  and	
  future	
  directions	
  
The history of reconstructive medicine and surgery dates back centuries as
physicians and scientists have continually sought to restore function to damaged tissue.
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Vascular tissue engineering began its path towards clinical utility with the construction of
the first blood vessel model by Weinberg and Bell. In the ensuing years, several major
breakthroughs in biological vascular graft production have led this young field into its
first successful clinical applications. Vigorous research continues, as these clinical trials
are in their early phase; it is a matter of time before they are attempted in the United
States under FDA guidance.
In the last 30 years we have witnessed the success, and the various pros and cons
of the methodologies used to create neovessels. The first generation of tissue-engineered
arterial grafts represent a significant step forward, but several challenges remain to be
addressed. Approaches that rely on bioreactors require significant culture time, preclude
“off the shelf” availability and place the conduit at risk for contamination. Also, the cell
source remains challenging, as adult human SMC’s have limited number of passages in
vitro, precluding the development of a well-developed tunica media.

Finally,

standardized imaging algorithms for implanted grafts will provide a more structured
analysis of graft patency, dilation, and/or stenosis.
Undoubtedly, new approaches and techniques have yet to be developed. Modern
technology in polymer fabrication or assembly may yield a more ideal scaffolding
material. Advances in cell culture techniques may allow for faster production of artificial
tissue. Ultimately, a deeper understanding of the signaling cascades involved in cellular
interactions in neotissue development will be critical to the construction of third
generation grafts. Modification of the genetic and molecular constitution of cells may
lead to the development of tissue with selective maturation properties.

Employing

particle release technology, grafts may be constructed that would elute growth factors,
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cytokines or other molecular signals that may recruit host cell development onto
scaffolding material, doing away with the need for cell seeding altogether.
As this technology develops, successful clinical applicability will be paramount to
future implementation. The focus in the field remains on responsible development of
modern tools to combat disease that affect a large portion of the population. Potential
widespread use for TEBVs will be dependent on patient safety, and functionality of
TEBVs that is as least equal to currently used synthetic grafts. Through landmark
accomplishments and continued clinical achievements, we near the promise of artificially
constructing neotissues that replicate the function of the human body.
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STATEMENT	
  OF	
  PURPOSE:	
  
This project was designed to elucidate the cellular and molecular mechanisms through
which bone marrow-derived mononuclear cells (BMC) seeded onto a biodegradable
tubular scaffold develops vascular neotissue. Specific emphasis was placed on the role
and origin of seeded and native host cells in the developmental remodeling of these
scaffolds into fully integrated autologous blood vessels.
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HYPOTHESIS:	
  
1. Role of Seeded Cells
Seeded bone marrow-derived mononuclear cells (BMC) contain vascular progenitor cells,
which differentiate and proliferate into the mature endothelial and smooth muscle cells of
the developing engineered blood vessel.

2. Tissue Regeneration
Final graft neotissue is a chimeric tissue composed of vascular cells, originating from
both the bone marrow and in-growth of adjacent vascular tissue.
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SPECIFIC	
  AIMS:	
  
1) Develop a methodology to critically evaluate neotissue formation on the entire length
of small-diameter biodegradable scaffolds among differing mouse strains.

2) Evaluate the impact of cell seeding on the development of implanted tissue engineered
vascular grafts.

3) Employ genetically modified mouse models to determine the impact of inflammation
and platelet deficiency on patency rates and neotissue formation.

4) Distinguish the cellular origins of neotissue aggregation (bone marrow derived
progenitors vs. adjacent vasculature) on tissue engineered vascular grafts.
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PART	
  II.	
  METHODS:	
  
I contributed to the planning, design, gathering, analysis and interpretation of all
data presented. Specifically, I led the studies that 1) finalized our understanding of the
role of cell seeding and cytokine signalling, 2) developed a technique to study in-vivo
vascular neotissue and 3) studied the role of murine model genetic background on
neotissue development. The cell tracking work was carried out in a collaboration led by
Dr. Hibino and Dr. Villalona. All the work contained in this thesis is the direct result of
close collaborations, contributions and expertise from all those acknowledged. Methods
carried out principally by collaborators are noted.
This study was conducted in accordance with the institutional guidelines for the
use and care of animals, and the institutional review board approved the experimental
procedures described below. Histologic processing/embedding of samples was done by
the Yale Core Center for Musculoskeletal Disorders (NIH/NIAMS AR46032). Schematic
illustration in Figure 5 done by Wendy Hill.

Construction	
  of	
  small-diameter	
  biodegradable	
  scaffolds	
  
PGA-P(CL/LA) scaffold construction:
A dual cylinder chamber molding system was constructed by Tony DeSimone
(Yale University School of Medicine Machine Shop) from a 6.5mm diameter
polypropylene rod. A 1.4mm diameter inner cylinder was cored through the center of the
rod for a length of 30mm and gradually tapered out to 6.0mm at the inlet (below).
Polyglycolic acid (PGA) nonwoven felt [ConcordiaFibers, Coventry, RI] was used for the
framework of the scaffold. The PGA felt was 300µm thick with approximately 90% total

26
porosity. The gradual taper of the inner cylinder enabled flat PGA felt sections (6.0mm x
4.0mm) to be easily shaped into tubes during their insertion through the inlet of the dual
cylinder chamber system. A 21-gauge stainless steel needle was then introduced into the
opposing end to maintain the inner lumen and further compress the felt. A 50:50
copolymer sealant solution of ε-caprolactone and L-lactide (P(CL/LA)) [263,800Da,
Absorbable Polymers International, Birmingham, AL] was created by dissolving the
copolymer at 5% (w/v) in 1,4-dioxane. The P(CL/LA) sealant was injected into the inlet

Schematic of scaffold fabrication using the dual cylinder chamber system. A) Flat PGA felts were
easily rolled into tubular constructs using a gradually tapered cylinder. B) P(CL/LA) solution sealed
the nonwoven PGA tube by creating an interconnecting porous structure between the PGA fibers.
C) Cross sectional image demonstrating the configuration of the components and removal of
solvents by lyophilization. D) Resultant hybrid polyester scaffold pushed out through inlet after
inner needle cylinder removed.
Adapted from Roh et al. Small-diameter biodegradable scaffolds for functional vascular tissue
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of the chamber system and allowed to penetrate the felt and fuse the open seam. The
hybrid polyester scaffolds were snap-frozen at -20°C for 30 min to enable rapid
transformation of the P(CL/LA) sealant from liquid to solid phase, creating a sealed tube
with a newly defined porous structure of P(CL/LA) copolymer interconnecting the PGA
fibers. The scaffolds were lyophilized for 24 hrs to eliminate the solvents before
removing them from the dual cylinder chamber system.

Structural characterization of PGA-P(CL/LA) scaffold:
Scaffolds were cut into 0.5mm thick cross-sections and imaged on a FEI XL-30
scanning electron microscope (SEM) [Hillsboro, OR]. Lumen diameters and wall
thickness were measured from high magnification SEM images.
The porosimetry profile of the scaffold was done by Tyrone Hazlett (Concordia
Fibers) and acquired by micro-computed tomography (microCT) imaging [Scanco
Medical microCT 40, Southeastern, PA]. Briefly, a 2048 x 2048 image matrix size over a
12.288mm field of view with 6µm slice increments was used to create an isotropic voxel
size of 6µm. A total of 200-250 slices were acquired for each scaffold section, and
images were then binarized by applying a small gauss noise reduction filter using fixed
threshold. Three-dimensional morphometric parameters as well as thickness and
separation distribution maps were generated using previously published methods(52).

Previous biomechanical characterization and biocompatibility assessment of PGAP(CL/LA) scaffold was conducted by Dr. Jason Roh, MD.
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Bone	
  marrow-derived	
  mononuclear	
  cell	
  (BMC)	
  isolation	
  and	
  
characterization	
  
BMC isolation:
Murine bone marrow was isolated directly from freshly harvested mouse femur
bones. A 25-gauge needle was inserted into the inter-trochanteric space and the bone
marrow was flushed out with Iscove’s Modified Dulbecco’s Medium (IMDM).
Unfractionated human bone marrow (10 donors, aged 21-44) was purchased from Lonza
[Walkersville, MD].
Both human and mouse BMCs were isolated by density gradient centrifugation.
Bone marrow was diluted 1:1 in sterile PBS and filtered through a 100µm nylon filter to
remove bone and fat fractions. The diluted bone marrow was then layered onto either
histopaque-1077 [human, Sigma] or histopaque-1083 [mouse, Sigma], and spun at 400g
for 30 min. The buffy coat, containing the mononuclear cells, was collected and washed
three times in sterile PBS prior to evaluating cell counts with a hemocytometer and cell
viability with trypan blue exclusion.

BMC seeding onto PGA-P(CL/LA) scaffolds:
A fibrin gel solution was used to attach BMCs to the scaffold. Briefly, BMCs
were suspended in a sterile fibrinogen solution (100mg/ml human fibrinogen [Sigma] in
PBS) at a concentration of 2x106 cells/ml. Fifty microliters of BMC-fibrinogen solution
(1x106 BMCs) was statically seeded onto each scaffold. The cell solution was solidified
onto the scaffold by adding 2 drops of sterile thrombin solution (100U/ml human

29
thrombin [Sigma] in 40mM CaCl2 in PBS). Seeded scaffolds were incubated at 37°C in
RPMI-1640 medium with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin
(P/S) until ready to be surgically implanted. All scaffolds were implanted within 48hrs of
seeding.

Characterization of human BMC sub-populations:
Isolated BMCs were characterized by fluorescence activated cell sorting (FACS).
Cells were resuspended in PBS with 0.5% FBS, 0.5% human AB serum and 0.1% sodium
azide, and then transferred to tubes (106 cells/tube) containing saturating concentrations
of a cocktail of antibodies. Antibodies used were purchased from BD Biosciences [San
Jose, CA] CD8 PerCP (SK1), CD14 FITC (M5E2), CD31 FITC (WM59), CD34 PE and
PerCP-Cy5.5 (8G12), CD45 APC-Cy7 (2D1), CD56 PE (NCAM16.2), CD146 (P1H12),
CD73 PE (AD2), CD90 FITC (5E10), 7AAD; E-Bioscience [San Diego, CA] CD3 APC
(HIT3a), CD4 FITC (L3T4), CD19 (PE-Cy7); Miltenyi Biotec [Auburn, CA] CD133
APC (AC133); R&D Systems [Minneapolis, MN] VEGFR2 PE (89106); and AbD
Serotec [Raleigh, NC] CD105 Alexa 647 (SN6).
To identify mature endothelial cells (EC), BMCs were incubated with CD45
APC-Cy7, CD31 FITC, CD146 PE, CD133 APC and the vital dye 7AAD (to exclude
dead cells). Mature ECs were identified as being CD45-CD133-CD31+CD146+. Early
outgrowth endothelial progenitor cells (E-EPC) were identified by staining with CD14
FITC (+ve), VEGF-R2 PE (+ve), and 7AAD (-ve). Late outgrowth EPCs (L-EPC) were
identified by staining with CD45 APC-Cy7 (-ve), VEGF-R2 PE (+ve), CD133 APC
(+ve), and 7AAD (-ve). Mesenchymal stem cells were identified using the panel of
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antibodies recommended by Dominici et al (44). MSC were defined as CD45-CD34CD105+CD73+CD90+ using the staining panel CD45 APC-Cy7, CD34 PE-Cy5.5, CD90
FITC, CD105 Alexa 647 and CD73 PE. Hematopoietic stem cells (53) were identified
using the antibodies CD45 APC-Cy7 (+ve), CD133 APC (+ve), CD34 PE (+ve) and
7AAD. Percentages of mature lymphocyte populations were determined using the
following antibodies: CD45 APC-Cy7 (+ve) for all lymphocytes; CD3 APC (+ve) and
CD4 FITC (+ve) for CD4+ T cells; CD3 APC (+ve) and CD8 PerCP (+ve) for CD8 T
cells; CD56 PE (+ve) and CD3 (-ve) for NK cells; and CD19 PE-Cy7 (+ve) for B-cells.
Cells were acquired on a FACSAria cell sorter and results analyzed using DIVA
software [BD Bioscience] by Dr. Lesley Devine.

Cytokine release profile of human BMCs:
Human BMCs were cultured in RPMI-1640 medium supplemented with 10%
FBS and 1% P/S at a concentration of 2x106 cells/ml. Cells were stimulated with PGAP(CL/LA) scaffolds or 10ng/ml of recombinant human interleukin-1beta [IL-1ß; R&D
Systems] for 48hrs. IL-1ß, vascular endothelial growth factor (VEGF), monocyte
chemoattractant protein-1 (MCP-1), and stromal derived factor-1alpha (SDF-1α) levels in
the cell culture supernatant were measured using enzyme linked immunosorbent assays
(ELISA) according to the manufacturer’s instructions [R&D Systems].
Multiplex Luminex (Millipore) immunoassay was employed to quantify multiple
cytokines simultaneously. The Luminex Assay uses dual laser capture to quantify multiple
cytokines that bind to antibody-coated microbeads simultaneously and specifically. Polystyrene
microspheres (5.6 microns) that carry a unique spectral signature and a cytokine specific antibody
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are admixed with supernatant. Cytokines were quantified via laser capture using a Luminex 200 v
.2.3 reader. 17 distinct cytokines were evaluated simultaneously – Eotaxin, Fractalkine, GCSF,
GM-CSF, GRO, IFN-gamma, IL-1beta, IL-6, IP-10, MCP-1, MIP-1alpha, MIP-1beta, PDGFBB, RANTES, sCD40L, TNF-alpha, and VEGF.

Detection of human RNA in TEVG.
TEVG harvested 1, 3, 7, or 21 days post-implantation or immediately prior to
implantation were snap-frozen in liquid nitrogen, and RNA was extracted by mechanical
crushing over dry ice followed by incubation in RLT lysis buffer (Qiagen). Samples were
passed through Qiashredder columns and processed using RNeasy mini kits according to
the manufacturer’s protocol (Qiagen). Reverse transcription with random hexamer and
oligo-dT primers was performed according to the Multiscribe RT system protocol
(Applied Biosystems). PCR reactions were prepared with TaqMan 2x PCR Master Mix
and pre-developed assay reagents from Applied Biosystems (human GAPDH,
Hs99999905 ml mouse HPRT, Mm00446968 ml). Species-specificity of the human and
mouse probes was confirmed on human and mouse control artery segments. To determine
the limits of human RNA detection, standard curves were generated by measuring human
GAPDH levels obtained from 10-fold serial dilutions of hBMC in culture and hBMC
seeded onto scaffolds. The limit of detection of this assay was between 10-100 cells.
PCR Analysis was conducted by Dr. Deepak Rao.
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Inferior	
  vena	
  cava	
  interposition	
  surgery	
  
Female C.B-17 severe combined immunodeficient/beige (SCID/bg) mice, aged 34 months, [Taconic, Rensselaer, NY] were anesthetized with an intraperitoneal injection
of xylazine and ketamine. Animals were then positioned supinely and opened with a
midline abdominal incision. Using a 5X dissecting microscope [Zeiss, Thornwood, NY],
infrarenal IVC was exposed, cross-clamped, and excised. Scaffolds were inserted as IVC
interposition grafts using a running 10-0 nylon suture for the end-to-end proximal and
distal anastomoses. All animal surgeries were done by Dr. Tai Yi. The animals were
recovered from surgery and maintained without the use of any anticoagulation or
antiplatelet therapy. Animals were sacrificed and grafts were explanted at various time
points.

Micro	
  computed	
  tomography	
  angiography	
  
Vascular grafts were examined by microCT analysis prior to explant to evaluate
patency and morphology. Animals were anesthetized with an intraperitoneal injection of
xylazine and ketamine, and anticoagulated with 100IU heparin prior to sacrifice. A PE-10
[polyethylene] catheter was inserted into the thoracic IVC and 300µl of Omnipaque
(300mg/ml) was injected into the venous circulation. Mice were imaged in an X-O*
microCT [Gamma-Medica, Northridge, CA]. Three-dimensional reconstruction was done
using COBRA software [Exxim Computing Corporation, Pleasanton, CA]. Images were
combined using Total Commander [Ghisler & Co., Switzerland] and volume rendered
with AMIDE imaging software [Loening, UCLA].

Micro-CTA with modified protocol:
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In vivo patency and morphology of the TEVGs were evaluated 24 weeks after
implantation using micro-CTA. Mice were positioned in supine position and placed on
animal bed of micro-CT scanner (eXplore CT120, GE Healthcare, USA). All animals
were imaged using standard micro-CT imaging protocol (220 views, 16 ms X-ray
exposure time, penetration energy: 70kV/32mA). Omnipaque contrast (GE Healthcare,
USA) was utilized as a contrast agent. Micro-CT images were reconstructed and
visualized with MicroView (GE Healthcare, USA) and Amide (amide.sf.net) software
packages to assess graft patency and vessel lumen size.

Explanted	
  tissue	
  engineered	
  blood	
  vessel	
  characterization	
  
Histology:
Explanted scaffolds were fixed in 10% NBF for 18 hrs and then paraffinembedded. Unstained 5µm sections were stained with H&E, Gamori trichrome
(collagen), and Verhoeff-van Gieson (elastin). Using previously published methods, some
pre-implant scaffolds were embedded in glycolmethacrylate to maintain better histologic
structure with processing(52).

Immunohistochemistry:
Immunohistochemical analysis was done on unstained 5µm sections using
species-specific antibodies to distinguish between human seeded cells and murine host
cells. Human-specific primary antibodies used were mouse-anti-human CD31 [1:100,
Dako, Carpinteria, CA], CD68 [1:500, Dako], CD34 [1:2000, Abcam, Cambridge, MA],
and CD45 [1:100, AbD Serotec]. Mouse-specific primary antibodies used were rat-antimouse Mac-3 [1:50, BD Bioscience], F4/80 [1:2000, AbD Serotec], IL-1ß [1:100, R&D
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Systems], and goat-anti-mouse VEGF-R2 [1:50, R&D Systems, minimal crossreactivity]. Primary antibodies that cross-reacted with both species were mouse-antihuman α-smooth muscle actin (αSMA) [1:1000, Dako], rabbit-anti-human von
Willebrand Factor (vWF) [1:2000, Dako], and mouse-anti-human VEGF [1:100, Santa
Cruz Biotech, CA]. Rabbit-anti-mouse to c-kit (Abcam), mouse-anti-mouse to Sox-2
(R&D Systems), and rat-anti-mouse Sca-1 (R&D Systems)Antibody binding was
detected using appropriate biotinylated secondary antibodies [Vector], followed by
binding of streptavidin-HRP [Vector] and color development with DAB [Vector]. Nuclei
were then counterstained with hematoxylin. For vWF detection, a goat-anti-rabbit IgGAlexa Fluor 568 [1:500, Molecular Probes, Eugene, OR] was used with subsequent 4',6diamidino-2-phenylindole (DAPI) nuclear counterstaining [Vector].

Quantitative cellular analysis:
To evaluate the cellular development of the scaffolds, the cellularity at each time
point (n=2-7) was measured by taking representative images of explanted scaffold crosssections. Two 5µm cross-sections, located at approximately 1/3 and 2/3 the distance from
the proximal to distal anastamosis, of each scaffold were stained with H&E. Six
photomicrographs were taken at 400X magnification to represent the entire cross-section,
and cell nuclei were counted and averaged.
Scaffolds explanted at post-operative wk 1 were also stained with an anti-F4/80
antibody, by methods described above, to specifically evaluate the early recruitment of
mouse monocytes to the scaffold. Again, two cross-sections, located at 1/3 and 2/3 the
distance from the proximal to distal anastamosis were examined. Six photomicrographs
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were taken at 400X magnification to represent the entire cross-section, and F4/80 positive
cells were counted and averaged.
Further explants were sectioned at specified intervals throughout the length of
TEVG scaffolds (3mm) with systematic measurements of graft morphology, including
explant diameter, radius, lumen circumference, outer graft circumference, and lumen
surface area. Measurements were conducted in triplicate and compared across samples
and within samples.

Development	
  of	
  MCP-1	
  eluting	
  scaffold:	
  
MCP-1 encapsulation in alginate microspheres:
Alginate microspheres, encapsulating recombinant human MCP-1 [R&D
Systems], were prepared by Steven Jay using a modification of an emulsification
technique developed by Zheng et al (46). Briefly, endotoxin-free alginate (18mg/ml) and
hydroxypropylmethylcellulose (HPMC) (2mg/ml) [Sigma] were co-dissolved in ultrapure
water, followed by direct dissolution of MCP-1 (50:1) at 1mg/ml. The resulting solution
was added to iso-octane + 5% (v/v) Span 80 while homogenizing at 17,500rpm. Tween
80 was added to the emulsion in order to create a favorable HLB value for microsphere
formation. After mixing, filtered 700mM CaCl2 solution or filtered 700mM ZnCl2
solution (pH=7) was added at a rate of 3ml/min to cross-link the alginate. Microspheres
were cured, spun down at 4,000rpm, and washed twice in 2-propanol. Microspheres were
then air-dried, resuspended in sterile water, and lyophilized. ZnCl2 cross-linked
microspheres underwent an additional immersion in M199 medium for 4 hrs, and were
again filtered and lyophilized. All MCP-1 alginate microspheres were stored at -20oC
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until use. ZnCl2 and CaCl2 cross-linked particles were used at a ratio of 1:1 for all
experiments. This work was carried out by Dr. Jason Roh, Dr. Steven Jay and RFSM.

Incorporation of MCP-1 microspheres in scaffold:
MCP-1 alginate microspheres (50mg/ml) were suspended in a 5% (w/v) solution
of P(CL/LA) in 1,4-dioxane. Scaffolds were then constructed using the dual cylinder
chamber system according to methods outlined above. Characterization of the
microspheres embedded in the scaffold was done using scanning electron microscopy.

Controlled release profile of MCP-1 eluting scaffolds:
MCP-1 eluting scaffolds (n=4) were immersed in 1ml of M199 medium and
incubated in a 37°C orbital shaker. At 1, 2, 4, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hrs,
the medium was collected and replaced with 1ml of fresh M199 medium. Media samples
were stored at -20°C until analysis. MCP-1 content in the samples was quantified by
ELISA according to the manufacturer’s instructions [R&D Systems].

Transgenic	
  Animals	
  
Transgenic inbred C57BL/6 mice that express green fluorescent protein (GFP)
under the control of ubiquitin-C promoter were obtained from the (Jackson Laboratory,
Bar Harbor, Maine) and bred in our laboratories. Other transgenic animal models used
are described above and elsewhere. All animal procedures were approved by the
Institutional Animal Care & Committee (IACUC) at Yale University.
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Fate	
  of	
  TEVG	
  Seeded	
  Cells	
  
Six to eight-week-old (20-25 grams) C57BL/6 mice underwent implantation of
IVC interposition grafts using a previously approved protocol, seeded with 1 x 106 cells
of GFP (+) BMMC. Mice were sacrificed post-operatively at 6-hours (N=4), 1-day
(N=4), 3-days (N=4), 7-days (N=4) and 14-days (N=4) and the grafts were explanted at
discrete time points to asses for fate of seeded cells using quantitative real time PCR.

Cell	
  Quantification	
  Assay	
  
The cellularity of each GFP (+) BMMC seeded scaffolds was determined by
measuring the DNA content with the PicoGreen detection assay (Molecular Probes,
Eugene, OR). At 6-hours, 1-day, 3-days and 7-days of incubation, seeded scaffold
sections were rinsed three times in 1mL PBS, placed in 200uL of distilled water, and
stored at -80C. At the time of evaluation, scaffold sections were thawed at 37.8C. A black
96-well plate was loaded with 50 uL from each sample. A 30ul aliquot of the PicoGreen
dye was mixed thoroughly with 6ml of Tris-EDTA buffer (pH 7.5) and 50ul was added to
each sample in the 96-well plate. All samples were performed in triplicate. The plate was
incubated in the dark at room temperature for 10 minutes. Fluorescence was measured at
488 nm excitation and 525 nm emission. The number of cells maintained on each
scaffold was determined from a standard curve generated from a known quantity of
mouse BMMC. A negative control of unseeded scaffold sections was used for
comparison (Roh et al., 2007)(Villalona et al 2010).

	
  
Cell	
  Viability	
  Assay
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In order to determine GFP+ BM-MNC viability following seeding onto scaffold
sections and incubation at 6-hours, 1-day, 3-days and 7-days a CellTiter 96® AQueous
Non-Radioactive Cell Proliferation Assay (Promega BioSciences, San Luis Obispo, CA)
was performed. After seeding, all scaffold sections were incubated in 2ml of RPMI 1640
media (1% penicillin/streptomycin and 10% fetal bovine serum) for the respective
incubation times. Media was changed every two days. Following incubation, the scaffold
sections were washed 3 times with 1ml PBS and the assay reagent (tetrazolium
compound (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)2H-tetrazolium, inner salt; MTS) and an electron coupling reagent (phenazine
methosulfate; PMS)) was added to each scaffold section in a 1:4 ratio with media and
allowed to incubate for 4 hours at 37C. After 4 hours, a 100ul aliquot of each sample was
added to a clear 96-well plate and the absorbance at 490nm was read. The relative cell
viability was determined by the ratio of absorbance from the seeded scaffold sections
incubated at different time points.

Bone	
  Marrow	
  Transplantation	
  	
  
After myeloablation with 900cGy total body irradiation using a 137 Cs source,
six-week old female wild-type C57BL/6 mice received a tail vein injection of 5x106
unfractionated nucleated bone marrow cells harvested from age matched, gender
mismatched (male) GFP (+) transgenic mice, as previously described (Di Lorenzo et al.,
2009). We confirmed engraftment of the bone marrow one month after bone marrow
transplantation by determining the percentage of GFP (+) cells on peripheral blood using
FACS. Subsequently TEVG (N=57) were implanted as IVC interposition grafts.
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Specimens for immunostaining (N=27) were explanted on post-operative day 3 (N=6), 7
(N=6), 14 (N=5), 10 weeks (N=5) and 6 months (N=5) and specimens for qPCR (N=30)
were explanted on post-operative day 3 (N=6), 7 (N=6), 14 (N=6), 10 weeks (N=6) and 6
months (N=6).

Composite	
  graft
The vena cava was harvested from a male mouse. One-millimeter sections of the
vena cava were anastomosed to the distal end of a scaffold. The composite scaffold was
then seeded and incubated as described above. The composite TEVG was implanted in a
female host (N=8). Specimens were harvested on post-operative day 7 (N=2), 14 (N=2),
at 10 weeks (N=2) and 6 months (N=2).

Quantitative	
  Real	
  Time	
  PCR	
  (qRT-PCR)	
  	
  
Explanted tissue grafts were incubated overnight in 180 µl of lysis buffer
(QIAGEN) and proteinase K (12 mAu/reaction) at 56°C. Following tissue digestion,
DNA was isolated from samples using DNeasy Blood and Tissue Kit (QIAGEN)
following manufacturer’s instructions. The following primers and TaqMan probe were
designed to amplify a specific 93 bp region of the GFP gene: forward, 5’ACCACATGAAGCAGCACGACTTCT-3’;

reverse,

5’-TGTAGT

TGCCGTCGTCCTTGAAGA-3’; probe, 5’-AAGGCTACGTCCAGGAGCGCACC AT3’. DNA amplification and quantification was performed using iCycler iQ Real-Time
PCR Detection System (Bio-Rad, Hercules, CA, USA). Each qPCR reaction consisted of
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the following steps: 2 min UNG incubation at 50°C to remove possible amplicon
contamination, followed by 10 min at 95°C to activate the polymerase, and 40 cycles of
15 sec denaturing at 95°C and 1 min at 60°C of extension and annealing. Data were
collected at the end of each elongation step and analyzed with iCycler iQ Real Time
Detection System Software (Bio-rad).

Fluorescent	
  in	
  situ	
  Hybridization	
  (FISH)	
  
FISH was performed on paraffin sections using digoxigenin-labeled mouse Y
chromosome probe detected using a Rhodamine-conjugated antibody to digoxigenin
(Roche Diagnostics, Mannheim, Germany) as previously described (Jones et al.,
1996)(Krauss et al., 2001). Counting of Y-positive nuclei was accomplished by
systematically examining the FISH-stained tissue, field by field, under 40X
magnification, using a Zeiss Axiovert 200M Fluorescence/Live cell Imaging Microscope
(Carl Zeiss Imaging Solutions, Thornwood, NY). Digital images were acquired using the
Zeiss LSM510 confocal computer system (Carl Zeiss Imaging Solutions, Thornwood,
NY). Images were pseudocolored using image processing software (Adobe Photoshop,
San Jose, CA). Cell counts were obtained by first counting all of the Y chromosomepositive cells in a defined area on the tissue, and then counting the total number of cells
in that area using the immunostained photographs.
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Statistical	
  analysis:	
  
Statistical differences were measured using a Student’s t-test. P values less than
0.05 were considered statistically significant.
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Part	
  III.	
  Results	
  	
  
Human	
   BMC-seeded	
   biodegradable	
   scaffolds	
   transform	
   into	
  
functional	
  blood	
  vessels	
  in	
  the	
  SCID/bg	
  mouse	
  	
  
The first objective of this study was to determine if the SCID/bg mouse could be utilized
as an animal model to study human TEVG development. Specifically, we looked to see if
similar results could be obtained in the SCID/bg mouse host as compared to human
recipients; i.e., that hBMC-seeded scaffolds transformed into functional venous conduits
in high flow, low pressure settings. TEVG were constructed under similar conditions to
the Shin’oka clinical study(18) protocol (6-8), and followed over a 24 wk course as IVC
interposition grafts. All hBMC-seeded TEVG (n=28) remained fully patent and
functional as venous conduits (Fig. 1A). At 24 wks, TEVG (n=5) (Fig. 1C-D)
morphologically and histologically resembled the native mouse IVC (Fig. 1F-G). As
early as 10 wks, endothelial cells (EC) lined the inner lumen and were invested by a
surrounding layer of SMC (Fig. 1H-I). By 24 wks, a mature vascular architecture,
consisting of a confluent EC-lined intima and 1-2 layers of SMC media, were clearly
defined in the neovessel (Fig. 1J). The original scaffold material had degraded by 24 wks,
and was effectively replaced by a supportive adventitial layer composed of
circumferentially oriented collagen fibrils (Fig. 1K-L). No elastin was detected in the
TEVG or native mouse IVC.

Stem	
  cells	
  constitute	
  a	
  minor	
  fraction	
  of	
  seeded	
  hBMC	
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To test if seeded hBMC were differentiating into the mature vascular cells of the
engineered neovessel, we first examined the phenotypes and relative abundances of cell
populations within the human BMC population used for seeding (Table 1). We
specifically searched for mature EC and SMC and progenitor cells capable of
differentiating into mature vascular cells. Human BMC consisted mainly of mature
leukocyte populations, including monocytes (10±4.7%), CD4+ T cells (7.0±2.7%), CD8+
T cells (7.9±2.5%), B cells (6.4±2.1%), and NK cells (3.2±1.4). A relatively high
percentage

of

CD146+CD31+CD45-

mature

bone

marrow

microvascular

EC

(0.050±0.024%) was also present. The largest population of adult stems cells identified
were CD34+ hematopoietic stem cells (1.8±0.53%). AC133+KDR+CD45- proangiogeneic
cells

made

up

0.0029±0.0042%

of

the

hBMC

population,

while

CD90+CD73+CD105+CD45-CD34- mesenchymal stem cells constituted the smallest
percentage of hBMC, with yields of only 0.0013±0.00096%.

Static seeding of hBMC into scaffolds resulted in a similar distribution of cell types as in
the original population, i.e., there was no obvious preference for any particular subpopulation. Prior to implantation, the majority of hBMC in the scaffold were CD45+
mature leukocytes (Fig. 2A). CD31+ mature EC and CD34+ stem cells were also
identified, but in much lower numbers (Fig. 2B-C). No alpha-smooth muscle actin
(αSMA) expression was detectable prior to implantation.
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Seeded	
  hBMC	
  are	
  not	
  incorporated	
  into	
  the	
  developing	
  TEVG	
  
Next, to determine if seeded hBMC were directly contributing to the vascular cell
composition of the developing neovessel, we tracked the seeded hBMC using humanspecific markers and immunohistochemistry. TEVG were explanted at various time
points over a 24wk timecourse and stained for various hBMC surface antigens. CD34+
human stem cells could no longer be detected in any of the TEVG after implantation. A
small number of CD68+ human monocytes and CD31+ human EC could be found within
the scaffold wall at 1 wk, but were not detectable after that time point (Fig. 2D-E). Lack
of seeded hBMC retention was confirmed with quantitative RT-PCR, demonstrating no
detectable human RNA in the scaffolds after 1 wk in the mouse host (Fig. 2I).

TEVG	
  are	
  composed	
  of	
  recruited	
  murine	
  host	
  cells.
Despite the diminishing presence of seeded hBMC, overall cellularity of the TEVG
increased markedly during the first week of in vivo development (Fig. 3A). This
increased cellularity stabilized after 1 wk, and was primarily due to rapid infiltration of
host mouse monocytes within the scaffold wall (Fig. 2F, 3B). Monocyte infiltration was
subsequently followed by the influx of α-SMA expressing cells around the inner luminal
lining (Fig. 2G). By 3 wks, partial endothelialization along the inner luminal lining could
be detected (Fig. 2H), and by 24 wks, the scaffold had been replaced by a mature
vascular structure (Fig. 1). Monocyte contribution to the cellularity of the TEVG
diminished concomitantly with scaffold degradation.

Seeded	
  hBMC	
  increase	
  early	
  monocyte	
  recruitment.
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With direct evidence showing seeded hBMC were not present after 1 wk in vivo, we next
investigated if they had any effect on the vascular development of TEVG by comparing
the cellularity of hBMC-seeded scaffolds to unseeded scaffolds (Fig. 3A). At postimplantation days 1 and 3, no significant differences in cellularity could be detected
between hBMC-seeded scaffolds and unseeded scaffolds. However, by day 7, the
increase in cellularity was significantly greater for hBMC-seeded scaffolds compared to
unseeded scaffolds (270±22 cells/hpf vs. 160±40 cells/hpf; p<0.001) (Fig. 3A). This
increased cellularity was primarily due to a significantly increased infiltration of host
mouse monocytes into hBMC-seeded scaffolds, as compared to unseeded scaffolds
(120±20 monocytes/hpf vs. 60±12 monocytes/hpf; p<0.001) (Fig. 3B).

Human	
   BMC	
   secrete	
   significant	
   amounts	
   of	
   MCP-1	
   when	
   seeded	
  
onto	
  scaffolds.	
  	
  
Based on the above findings, we hypothesized that seeded hBMC were functioning via a
paracrine mechanism instead of directly differentiating into the vascular cells of the
developing neovessel. To investigate this potential function, we examined the interaction
hBMC had with scaffold biomaterials to determine if scaffold exposure activated hBMC
to secrete chemokines that could increase early monocyte recruitment. Scaffold exposure
significantly increased the production of multiple cytokines and chemokines by seeded
hBMC (Fig. 3C-E). In particular, significantly high levels of MCP-1 were found to be
secreted by seeded hBMC (Fig. 3C, 3F). MCP-1 levels induced by hBMC seeding
reached quantities comparable to MCP-1 levels used in prior arteriogenesis studies (12,
13). Based on the levels obtained, MCP-1’s known function as a potent monocyte
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chemokine, and its established link to postnatal neovascularization (12-15), we chose to
investigate whether MCP-1 might be playing a role in TEVG development.

Local	
   MCP-1	
   secretion	
   from	
   scaffolds	
   increases	
   early	
   monocyte	
  
recruitment,	
  

mimicking	
  

seeded	
  

hBMC	
  

effects	
  

on	
  

TEVG	
  

development.
With in vivo data suggesting that seeded hBMC increased early monocyte recruitment
and in vitro studies indicating hBMC secreted significant amounts of MCP-1 when
seeded onto scaffold materials, we hypothesized that seeded hBMC were increasing early
monocyte recruitment via MCP-1 secretion. To test this hypothesis, we developed a
system that enabled us to study the effects of secreted MCP-1, independent of other
cytokines potentially produced by seeded hBMC. This was accomplished by creating
hBMC analogues, capable of only releasing MCP-1. To create these analogues, we
encapsulated recombinant human MCP-1 into biodegradable alginate microparticles, 120µm in diameter, making them comparable in size to the heterogeneous population of
hBMC (Fig. 4A). The microparticles were then embedded into the scaffold to mimic the
MCP-1 secretion by seeded hBMC (Fig. 4B-C). Embedded microparticles released
approximately 200ng of MCP-1 from the scaffold over the course of 72 hrs, which was
similar to the duration of retention of seeded hBMC (Fig. 4D).
Unseeded scaffolds embedded with MCP-1 microparticles developed and
functioned similarly to hBMC-seeded scaffolds when implanted as IVC interposition
grafts in the SCID/bg mice. Host monocyte recruitment at 1 wk was significantly
increased in MCP-1 eluting scaffolds (200±60 monocytes/hpf), compared to both hBMC-
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seeded (120±20 monocytes/hpf; p<0.05) and unseeded (60±12 monocytes/hpf; p<0.05)
scaffolds (Fig. 4E). Furthermore, after 10 wks in vivo, all MCP-1 eluting scaffolds (n=5)
were functioning as patent venous conduits, and exhibited similar elements of vascular
remodeling to the hBMC-seeded scaffolds. The MCP-1 eluting scaffold was fully
infiltrated with host mouse monocytes, creating an external tube circumscribing an
internal lumen of organized vascular neotissue, consisting of a confluent endothelial
lining, smooth muscle medial layer, and circumferentially oriented collagen fibrils (Fig.
4F-K).

TEVG	
  form	
  neovessels	
  that	
  resemble	
  native	
  veins	
  
Miniaturized PGA-P(CL/LA) tubular scaffolds were seeded with syngeneic BMMC and
implanted into the inferior vena cava (IVC) of CB57BL/6 mice. Scaffold materials
completely degraded by six months, at which point TEVGs displayed similar vascular
architecture to a native vein. Three-dimensional computer tomography angiography of
TEVGs at six months showed no evidence of stenosis, aneurismal dilation or thrombosis
(figure 6a). Furthermore, histological characterization demonstrated a mature laminated
structure, consisting of an endothelialized intimal layer and smooth muscle medial layer
(figure 6b).

Fate	
  of	
  TEVG	
  seeded	
  cells	
  
The quantity of GFP-labeled cellular DNA within scaffolds was maximal at 6-hours after
over night incubation and the cellularity decreased following 1-day of incubation (figure
7a). These findings suggest the seeded cells decrease in number over time after in vitro
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culture, probably not attaching to scaffold and washed off with media changes. The
relative cell viability and activity of the seeded cells increased over a 7-day incubation
period (figure 7b). Despite low attachment of these cells to the TEVG, these cells remain
active and viable up to 7-days, suggesting that the cells are not dying with in vitro
cultivation. Following this we implanted TEVG (N=30) to six to eight-week-old C57Bl/6
mice constructed by seeding the scaffold with GFP-labeled syngeneic BMMC and then
harvested the scaffolds over at 6-hours, 1-day, 3-days, 7-days and 14-days quantifying
the percentage of GFP DNA at various time points. We found that the seeded syngeneic
cells disappeared as the scaffold became populated by host-derived cells identified as
F4/80 expressing macrophages (not shown). Immunofluorescence of grafts demonstrated
the presence of GFP-labeled cells within the graft at 6-hours, 1-day, 3-days, but no
remaining cells at 7-days post-implantation (figure 7c). GFP DNA qPCR corroborated
the findings that over the course of 14-days following implantation the concentration of
GFP genomes decreased rapidly from 173 genomes/ul at 6-hours to 0.12 genomes/ul at
14-days (Figure 7d). We then standardized the GFP data to cell density to confirm that
the seeded cells disappeared. The percentage of GFP (+) cells per TEVG was found to
decrease from 4.37% at 6-hours to 0.02% at 14-days (Figure 7e).

Bone	
  marrow	
  cells	
  are	
  not	
  the	
  ultimate	
  source	
  of	
  vascular	
  
neotissue	
  
We next designed a series of experiments to determine the source of the cells that
populated the scaffold. To assess the role of host bone marrow cells (BMC) in neovessels
formation of our TEVG, chimeras were created by rescuing lethally irradiated C57BL/6
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female mice with gender mismatch male GFP (+) total BMC from transgenic GFPlabeled mice. Donor cell engraftment in the surviving recipients was determined five
weeks after bone marrow transplantation. Fluorescent activated cell sorting (FACS)
analysis of peripheral blood GFP-labeled mice demonstrated 97.74% circulating GFP (+)
cells in positive control mouse (figure 8a), 0.49% in negative control mouse (figure 8b)
and 94.06% reconstitution in transplanted mice (figure 8c). Once chimeras were
established, we implanted our TEVG into female mice. All mice were sacrificed at days
3, 7, 14-days, 10-weeks and 6-months post-implantation and all graft were harvested for
histological analysis. Three and seven days after implantation, Y Chromosome (+) (Y
Chr) cells were found in the graft wall, most of these male-derived BMC were
macrophages determined by colocalization for FISH Y (+) cells and F4/80 antibody using
immunofluorescence technique (not shown). At fourteen days as the number of BMC
increased within the graft wall, the presence of endothelial cells and smooth muscle cells
begin to appear. These vascular cells were positive for vWF and SMA markers, but
negative for Y Chr cells (figure 8d, 8e). Ten weeks after implantation a confluent
neointima (EC) and neomedia (SMC) are present; both layers are negative for YChr cells
(not shown). Finally, six months post-implantation the neovessel endothelial layer is
composed of vWF (+) YChr (–) cells (figure 9a). The smooth muscle layer is composed
of calponin (+) YChr (–) cells (figure 9b) and the scaffold is mostly degraded with few
inflammatory cells present that are positive for MAC-3 and Y Chr (+) (figure 9c). The
numbers of infiltrating BM-derived YChr (+) cells in the graft wall increased up to 10
weeks, while graft degradation is occurring, but at 6 months post-implantation these cells
markedly decrease (figure 9d). This acute inflammatory response and later decline was
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corroborated using qPCR for GFP DNA within the graft over a six-month period (figure
9e). These experiments demonstrated that the macrophages that initially infiltrated the
scaffold were of male origin. At later times a confluent layer of endothelial cells and
smooth muscle cells is present in the neovessel with no evidence of co-localization of
either smooth muscle cell markers or endothelial cell markers with the Y chromosome
(figure 9f).

Neovessel	
  formation	
  arises	
  from	
  in-growth	
  of	
  vascular	
  cells	
  from	
  
the	
  neighboring	
  blood	
  vessel	
  
To determine if the endothelial cells or smooth muscle cells derived from the neighboring
blood vessel, we developed a composite vascular graft created by anastomosing a
segment of syngeneic male IVC with a TEVG (figure 10a). These composite vascular
grafts (N=8) were implanted into female hosts and harvested on post-operative day 7, 14,
10-weeks and 6-months and processed for histological analysis and paraffin-embeding.
All composite grafts were cut with 5um in a longitudinal fashion to include the male
(donor) IVC, TEVG and female (host) IVC (figure 10a). The composite graft and
neighboring IVC were then evaluated using FISH to identify the Y-chromosome. Seven
and fourteen days post-implantation most of the graft wall is populated by MAC 3 (+)/Y
Chr (–) cells (host origin) and no confluent endothelial or smooth muscle cells layers are
noted (not shown). An endothelial (vWF +) and smooth muscle layer (calponin +) is
noted initially at fourteen days and then more confluent at 10 weeks post-implantation
(not shown). Finally at 6 months post-implantation, the host-derived neovessel is
composed of a confluent neointima, neomedia and a neoadventitia. Detailed analysis of
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the neointima and neomedia using confocal microscopy demonstrated that the percentage
of Y-chromosome positive endothelial and smooth muscle cells was greatest closer to the
implanted male IVC segment (figure 10b, c). These findings suggest that the resulting
neovessel is not derived from seeded cells or bone marrow progenitor cells but instead
through a locally mediated process of in-growth of neighboring endothelial and smooth
muscle cells from the surrounding native vessel. On immunohistochemistry, 6-month
sections were negative for stem cell markers and markers of progenitor cells including
Sca-1, c-kit, and Sox-2.

Part	
  IV.	
  Discussion	
  
In contrast to prior studies reporting that stem cells within seeded BMC
differentiate into the mature vascular cells of developing TEVG (32), we found no
evidence supporting this concept of a stem-cell mediated process of vascular
development. While we did identify small populations of hematopoietic and vascular
progenitor cells in the BMC population used for seeding (table 1), we did not detect any
human-derived BMC in the mature neovessel beyond one week post-implantation (Fig.
2). Rather, our data suggests that hBMC-seeded biodegradable scaffolds transform into
functional mature blood vessels via an inflammation-mediated process of vascular
remodeling that is expedited by the secretion of MCP-1 from the seeded hBMC (Fig.
5A).
A paracrine role of seeded BMC in the vascular remodeling of TEVG is
consistent with a number of studies reporting that transdifferentiation of bone marrowderived stem cells in vivo is rare (54-59). Mechanistic studies examining the role of BMC
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in cell therapies for ischemic diseases demonstrate that these cells do not differentiate
into mature EC or regenerating tissue, but instead function by releasing multiple
cytokines that induce therapeutic angiogenesis, arteriogenesis, and/or cytoprotection (5963). Early reports of transdifferentiation may be attributable to misinterpretations of cell
fusion (64-67). It is possible that cell fusion may also explain results of prior TEVG
studies, which used fluorescent membrane labeling techniques to track seeded BMC (32).
As determined in this study, monocytes/macrophages are the predominant cellular
infiltrate in TEVG, and are very adept at phagocytosis and cell fusion. To avoid potential
misinterpretations of cell fusion or auto fluorescence, we used peroxidase-based
immunohistochemistry to track seeded hBMC in an immunodeficient mouse host. As far
as we know, murine cells have never been shown to express human antigens in vivo.
Additionally, our chimeric hBMC-SCID/bg mouse model enabled us to further validate
our immunohistochemical findings with species-specific quantitative RT-PCR (Fig. 2I), a
method that could not be utilized in prior studies, which employed autologous BMC
sources (32, 68, 69).
What this study clearly demonstrates is that seeded BMC need not be directly
incorporated into the vascular neotissue of the developing TEVG in order to produce a
functional vessel. While much of the work in vascular tissue engineering has been
predicated on the concept that vascular development of these biodegradable grafts is
driven by seeded cells directly contributing to the mature vascular neotissue (17, 32, 33,
35, 47, 68-71), our findings suggest that seeded BMC may only play a transient indirect
role in the early stages of vascular transformation. A potential limitation of our model is
that the seeded BMC are human while the host is a mouse. Consequently, disappearance
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of the seeded cells may be a form of xenograft rejection not relevant to the clinical setting
in which autologous human cells are utilized. We think this is unlikely because the
immunodeficient SCID/bg mouse strain is unable to reject human hematopoietic or
vascular cells because both T cells and NK cells are defective. Despite this potential
problem, we elected to study human BMC because these cells may differ in their
properties from mouse BMC and effective mechanistic studies investigating their role in
TEVG development cannot be done in humans.
Interestingly, our findings revealed that vascular transformation of TEVG is not
driven by seeded BMC transdifferentiation and proliferation, but rather by the infiltration
of host monocytes (Fig. 5A). By secreting MCP-1, seeded hBMC alter the kinetics of the
early phase of vascular remodeling by expediting the recruitment of host monocytes to
the scaffold (Fig. 3A-B). Rapid early monocyte recruitment has been shown to be
intricately involved in postnatal blood vessel formation (72-74). In particular, successful
arteriogenesis is dependent upon MCP-1 induced monocyte recruitment to pre-existent
collateral arterioles (75-79). TEVG seem to follow a similar developmental pattern in
which a short pulse of MCP-1 (derived from scaffold-activated BMC vs. shear stressactivated EC/SMC) enables rapid monocyte recruitment to a pre-determined location of
blood vessel formation (biodegradable scaffold vs. collateral arteriole).
The exact roles recruited monocytes play in the vascular transformation of TEVG
are currently under active investigation in our laboratory. We hypothesize that host
monocytes have similar functions in TEVG development as they do in postnatal
neovascularization, including producing an important milieu of cytokines, growth factors,
and proteases necessary for vascular cell proliferation/migration and appropriate vascular
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remodeling (80, 81), Fig. 5A). In particular, continued vascular endothelial growth factor
(VEGF) expression has been shown to be critical in adult neovascularization for
appropriate cell recruitment and prevention of neovessel regression (82-84). Our
preliminary findings suggest a similar phenomenon in the vascular development of
TEVG. Recruited monocytes remain within the scaffold until it fully degrades. In
conjunction, we have seen VEGF expression within the scaffold wall throughout the
duration of monocyte/macrophage infiltration, suggesting a continued secretion of VEGF
by the infiltrating cells (Fig. 5B). Ultimately, it is likely that recruited monocytes produce
not only VEGF, but multiple molecular agents, which orchestrate the proper vascular
remodeling of the TEVG prior to scaffold degradation.
It must be noted that although the SCID/bg mouse has enabled us to study the
same population of human BMC being used in clinical TEVG trials and provided insight
into the mechanism of TEVG development, its lack of a functional adaptive immune
system may have effects on this process that we are unable to detect in an
immunodeficient host. Recent studies have suggested that regulatory T cells and NK cells
may play a role in modulating postnatal neovascularization (85, 86). One interesting
observation in the SCID/bg mouse was that a statistically significant difference in overall
patency rates was not detected between BMC-seeded and unseeded scaffolds, which may
be a reflection of the immunodeficient component of our mouse model. Prior studies
comparing BMC-seeded versus unseeded scaffolds in various immunocompetent species
have shown variable results in terms of patency, with results ranging from no significant
difference to a 60% reduction in patency without BMC seeding (68, 69). Despite these
discrepancies in preservation of patency, both studies reported that BMC seeding altered
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vascular remodeling of the graft in terms of extracellular matrix production, organization,
and cellularity. Further studies in immunocompetent mouse models will be necessary to
delineate what roles the adaptive immune system and recipient host play in TEVG
development. However, it is clear that BMC seeding exerts a significant effect on the
vascular remodeling of TEVG. For the first time, our study shows that seeded BMC
significantly affect the kinetics of vascular transformation by accelerating the rate of
neovessel development through increased early monocyte recruitment.
The second series of experiments in this study sought to determine the source of
the cells that make up the neotissue in our tissue engineered vascular grafts. In order to
accomplish this goal, we investigated the origins of the vascular neotissue cells in a
syngeneic immunocompetent mouse recipient using bone marrow chimeric hosts and
composite vascular implants.

Miniaturized PGA-P(CL/LA) tubular scaffolds were

seeded with syngeneic BMMCs and implanted into the mouse IVC to mimic the high
flow, low pressure venous setting seen in the clinical application for congenital heart
surgery.
Results of this study validate our previous work demonstrating the rapid
disappearance of the seeded cell from the TEVG, however this time performed in a
clinically relevant, immune competent murine model (87). To trace the fate of the
BMMC in this study, we implanted TEVG constructed by seeding the scaffold with GFPlabeled syngeneic bone morrow-derived mononuclear cells and then harvested the
scaffolds over a 2-week time course quantifying the percentage of GFP DNA at various
time points. As we had observed in the human into mouse xenogeneic model, we found
that the seeded syngeneic cells disappeared as the scaffold became populated by host-
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derived cells identified as F4/80 expressing macrophages. To demonstrate that this was
not simply a dilutional effect due to increased cell density secondary to the infiltrating
host inflammatory cells, we standardized the GFP data to cell density and confirmed that
the seeded cells disappeared. Also as with previous studies in other animal models,
scaffold materials completely degraded by six months, at which point TEVGs displayed
similar vascular architecture to a native vein (32, 68, 69).
To analyze the role of bone marrow-derived cells in vascular neotissue formation,
we implanted TEVG into female mice which had undergone bone marrow transplantation
with syngeneic male bone marrow and then harvested the TEVG at various times over a
six month period; we analyzed the specimens using FISH for the Y chromosome and a
variety of other cellular markers including markers for macrophages (F4/80), smooth
muscle cells (calponin), and endothelial cells (vWF). These experiments demonstrated
that the macrophages that infiltrated the scaffold were of male origin and were therefore
were derived from the bone marrow. When we looked at later times there was no
evidence of co-localization of either smooth muscle cell markers or endothelial cell
markers with the Y chromosome marker suggesting that the bone marrow was not the
source of the definitive vascular neotissue.
To determine if the endothelial cells or smooth muscle cells derived from the
neighboring blood vessel, we developed a composite vascular graft created by
anastomosing a segment of syngeneic male IVC with a TEVG. These composite vascular
grafts were implanted into female hosts and harvested over a six-month period. The
composite graft and neighboring IVC were then evaluated using FISH to identify the Ychromosome. Both endothelial cells and smooth muscle cells were found to contain the
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Y-chromosome. In addition, the percentage of Y-chromosome positive cells was greatest
closer to the implanted male IVC segment. These data suggest that definitive neovessel
cells arise from in-growth of cells, mostly likely differentiated endothelial and smooth
muscle cells, from the neighboring blood vessel segment. Although we cannot rule out
the possibility that there is a rare population of stem cells resident within the adjacent
vascular segment, we found negative immunohistochemical staining for markers of both
stem cells and progenitor cells, suggesting that it is the differentiated endothelial and
smooth muscle cells themselves that migrate in to create the neotissue.
In summary, this work has demonstrated the discovery of an inflammationmediated process of vascular remodeling that underlies the mechanism by which TEVG
transform into functional blood vessels in vivo. This mechanism of engineered vascular
formation displays many parallels to natural neovascularization (i.e. collateral
arteriogenesis) and may provide further insights into the biology of these processes.
However, while similarities to natural processes exist, TEVG development does appear to
be a distinct process of vascular formation in itself, which may have important
implications for the burgeoning field of vascular tissue engineering. Our findings suggest
that some of the core concepts used in engineering blood vessels from BMC-seeded
biodegradable scaffolds may be fundamentally flawed. In particular, inflammatory
responses to scaffold biomaterials may not necessarily be detrimental, and the importance
of seeded BMC may not be their role as progenitors of cellular constituents, but rather as
mediators for appropriate vascular remodeling and development.
Additionally, this study has demonstrated that the smooth muscle cells and
endothelial cells that make up the intima and media of the neovessel formed in our
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model, are derived from the neighboring blood vessel wall. Therefore, the cells of the
neotissue are not derived from either the seeded cells or from bone marrow derived
progenitors as has previously been suggested (47). While this may be a model-specific
phenomenon, it suggests that neotissue formation can be a form of augmented tissue
repair or regeneration.

This represents a shift away from the traditional tissue

engineering theory in which the seeded cells are viewed as the building blocks of the
neotissue and a moves towards a new paradigm in which the tissue engineered construct
promotes or augments the body’s own reparative mechanisms to induce tissue
regeneration.
A better understanding of how TEVG develop in vivo will lead to improved,
second-generation TEVG. Moreover, identification of key molecules, such as MCP-1,
may provide tissue engineers with the key to harnessing the body’s abilities to regenerate
therapeutic neovessels in vivo rather than having to fabricate them in vitro. These
findings have significant implications for rationally designing improved secondgeneration tissue engineered grafts based on the modulation of the host response to the
tissue engineered construct.
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Figure 1: Human TEVG, constructed from hBMC-seeded scaffolds, transform into living
blood vessels in the SCID/bg mouse. A) Micro-CT angiography at wk 10 shows a patent
TEVG functioning as an IVC venous conduit. Gross images of a human TEVG
interposed into the SCID/bg mouse IVC at B) operative day 0 and C) after 24 wks in
vivo. D) Gross image of native mouse IVC for comparison. Corresponding H&E images
of E) TEVG at day 0 (demonstrating hBMC transplanted into scaffold wall), F) TEVG at
24 wks (notice scaffold material has degraded), and G) native mouse IVC. Low
magnification (100X) photomicrographs of TEVG at 10wks post-implantation show
scaffold material still present, and the development of a confluent H) smooth muscle cell
(αSMA=brown) layer and I) endothelial cell (vWF=brown) lining throughout the inner
lumen. By 24wks, scaffold material has degraded and TEVG displays mature vessel
architecture. J) High magnification (400X) photomicrograph demonstrates an organized
endothelial intima (vWF=red) and SMC media (αSMA=green). K) Low magnification
(100X) photomicrograph of Verhoeff van Gieson stain shows scaffold has been replaced
by a circumferentially oriented supportive adventitial layer composed of collagen
(collagen=pink). L) High magnification (400X) Verhoeff van Gieson stain demonstrates
organization of collagen fibrils, but no elastin fibers (elastin=black, collagen=pink).
Figure 2: Seeded hBMC do not directly contribute to the cellularity of the developing
neovessel. Immunohistochemical analysis of pre-implant TEVG shows evidence of A)
human leukocytes (hCD45), B) human EC (hCD31), and C) human stem cells (hCD34).
Immunohistochemical analysis of hBMC-seeded scaffolds explanted at 1wk in vivo
detected only small numbers of retained D) human monocytes (hCD68) and E) human
EC (hCD31). No hCD34 was detectable. After 1 wk, no human antigen expression in the
TEVG was detectable via immunohistochemistry. F) Majority of cells in scaffold wall at
1 wk express F4/80, a marker for mouse monocytes/macrophages. G) Smooth muscle
actin (αSMA) expression starts to be detected around the inner luminal lining by 1wk. H)
Patchy endothelialization, indicated by positive vWF expression, begins to form in the
inner lumen by 3 wks. I) RT-PCR of explanted hBMC-seeded scaffolds confirms no
detectable human RNA expression after 1 wk in vivo. All photomicrographs at 400X
magnification (brown = positive expression). Data in graphs expressed as mean ± SD, *
p<0.05 **p<0.001.
Figure 3: Seeded hBMC increase early monocyte recruitment and secrete MCP-1. A)
Although seeded hBMC are no longer present after 1 wk in vivo, scaffold cellularity
rapidly increases during the first week of development, and then stabilizes until scaffold
degradation. Comparison between hBMC-seeded and unseeded scaffolds shows that
hBMC seeding increases early cellularity at 1 wk. B) The difference in cellularity
between hBMC-seeded and unseeded scaffolds at wk 1 is primarily due to significantly
increased numbers of mouse monocytes (positive F4/80 expression). C-E) Scaffold
exposure activates hBMC to produce multiple cytokines associated with monocyte
chemotaxis. Luminex assay shows increased expression levels of 12 of the 17 cytokines
evaluated when hBMC are seeded onto PGA-P(CL/LA) scaffolds. MCP-1 was expressed
in the highest concentration, with log fold differences over the other cytokines tested. IP-
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10 and PDGF expression are notably decreased by exposure to PGA-P(CL/LA) scaffolds.
F) Confirmatory MCP-1 specific ELISA shows significant increase in MCP-1 production
when hBMC seeded onto PGA-P(CL/LA) scaffolds. Data in graphs expressed as mean ±
SD, * p<0.05, ** p<0.001.
Figure 4: MCP-1 releasing microparticles mimic function of seeded hBMC by increasing
early monocyte recruitment. To investigate the potential role of MCP-1 secreted by
seeded hBMC, MCP-1-releasing microparticles were constructed from biodegradable
alginate. Scanning electron microscopy images of A) MCP-1 microparticles similar in
size distribution to hBMC (1-20µm), B) scaffold embedded with MCP-1 microparticles,
and C) higher magnification of scaffold, demonstrating individual PGA fibers with MCP1 microparticles securely embedded into the P(CL/LA) sealant. D) Cumulative MCP-1
release profile of MCP-1 microparticle scaffolds (n=5) shows they release approximately
200ng MCP-1 over 72hrs. E) At 1wk, MCP-1 microparticle scaffolds (n=3) have
significantly greater numbers of mouse monocytes (F4/80 positive cells) than both
hBMC-seeded (n=5) and unseeded scaffolds (n=5). At 10wks, all MCP-1 microparticle
scaffolds (n=5) were patent and demonstrated similar vascular architecture to hBMCseeded scaffolds. F) Immunohistochemical staining of the vWF antigen shows a
confluent endothelial intimal layer. G) An organizing smooth muscle media layer,
identified by α-SMA expression, was detectable below the intima. H) Gamori trichrome
staining shows supportive circumferentially oriented collagen fibrils within the vascular
neotissue and an external ring of degrading scaffold material. Photomicrographs of
hBMC-seeded scaffold stained with I) vWF, J) α-SMA, and K) Gamori trichrome, for
comparison. All histologic photomicrographs at 400X magnification. Data in graphs
expressed as mean ± SD; *p<0.05, **p<0.001.
Figure 5: Proposed mechanism of vascular transformation of TEVG composed from
hBMC-seeded biodegradable scaffolds. A) An early pulse of MCP-1, secreted from
seeded hBMC, enhances early monocyte recruitment to the scaffold. Activated
monocytes then release multiple angiogenic cytokines and growth factors, i.e. VEGF,
which recruits SMC and EC to the scaffold. Vascular cells potentially come from
circulating progenitors and/or proliferation/migration of mature vascular cells in the
adjacent vessel segments. EC and SMC appropriately organize into a mature blood vessel
structure on the luminal surface of the scaffold. As the scaffold degrades, monocytes
migrate away, leaving behind a completely autologous neovessel. B)
Immunohistochemical VEGF staining of hBMC-seeded scaffolds at post-implantation
wks 1, 6, and 10 shows continued VEGF expression throughout TEVG development
(brown = positive VEGF expression). All photomicrographs at 400X magnification.
Table 1: Flow cytometry characterization of human bone marrow mononuclear cells
used for seeding biodegradable scaffolds. Data accumulated from five different donors
and expressed as mean ± SD.
Figure 6: Representative CT angiogram of a TEVG IVC interposition graft six-months
after implantation (a). TEVG colored blue. Representative photomicrographs of
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immunohistochemical characterization of the native IVC compared to the TEVG sixmonths after implantation (H&E 100X) and (CD31 & Cal 400X) (b).
Figure 7: DNA Assay of scaffolds from 0 hr to 7 days of in vitro incubation, showed
increased number of cells in first 24 hours and loss of cells after 72 hours (a). MTS Assay
of scaffolds from 0 hr to 7 days in vitro incubation, showed initial increase in metabolic
activity followed by steady state (b). Invivo tracking using immunofluorescence (630X)
demonstrated GFP positive cells within the graft at 6 hours, 1 and 3 days, but no cells 7
days post-implantation (c). These findings were corroborated by qPCR of GFP DNA
from TEVG (N=30) seeded with GFP positive cells, implanted in GFP negative hosts,
and harvested between 6 hours and 14 days after implantation (d). Level of detection is
10 genomes/ul. Data in the graph are expressed as mean ± standard deviation. Percentage
of GFP-labeled cells per TEVG standardized for cell density decrease from 4.37% at 6hours to 0.02% at 14-days (e).
Figure 8: FACS analysis of GFP (+) mouse as positive control (a), C57BL/6 mouse for
negative control (b) and engraftment 5-weeks post-transplantation (c). Schematic
demonstrating components and orientation of photomicrographs for e and f (d).Confocal
microscopic images of TEVG implanted into female host that had undergone
transplantation with male bone marrow harvested 14-days after implantation
demonstrating no co-localization with the Y chromosome (Y-chromosome FISH) and
either (EC) endothelial cells (von Willebrand Factor, vWF, 630X) (e) or (SMC) smooth
muscle cells (Calponin 630X)(f).
Figure 9: Schematic demonstrating components and orientation of photomicrographs for
b (a). Confocal microscopic images of TEVG implanted into female host that had
undergone transplantation with male bone marrow harvested six-months after
implantation demonstrating co-localization of macrophages (MAC) and the Ychromosome (Y-chromosome FISH) but no co-localization with the Y chromosome (Ychromosome FISH) and either endothelial cells (von Willebrand Factor) or smooth
muscle cells (Calponin) (400X) (b). The numbers of infiltrating BM-derived Y
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chromosome (Y-chromosome FISH) cells (Bone marrow cells/High power field)in the
graft wall increased up to 10 weeks, while graft degradation is occurring, but at 6 months
post-implantation these cells markedly decrease (c). This was quantified and corroborated
using qPCR for GFP DNA within the graft over a six-month period (d). Confocal
microscopic image of triple staining of a six-month neovessel with normal IVC
configuration with single layer neointima (EC: vWF/light blue), neomedia (SMC:
calponin/green) and neoadventiacia with scattered inflamatory cells (Male: Ychr/red) (e).
Figure 10: Schematic demonstrating composite TEVG (N=8) created by anastomosing a
syngeneic male IVC with a TEVG and implanted into a female host harvested six-months
after implantation and the percentage of cells with Y-chromosome as a function of
distance from the male IVC (a). Confocal microscopic images of demonstrating colocalization of endothelial cells (von Willebrand Factor) and Y Chromosome (Ychromosome FISH)(400X) (b). Photomicrographs demonstrating co-localization of
smooth muscle cells (calponin) and Y Chromosome (Y-chromosome FISH) (400X) (c).
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